243 related articles for article (PubMed ID: 12847678)
1. Polymorphism at position -308 of the tumor necrosis factor alpha gene influences outcome of infliximab therapy in rheumatoid arthritis.
Mugnier B; Balandraud N; Darque A; Roudier C; Roudier J; Reviron D
Arthritis Rheum; 2003 Jul; 48(7):1849-52. PubMed ID: 12847678
[TBL] [Abstract][Full Text] [Related]
2. Influence of -308 A/G polymorphism in the tumor necrosis factor alpha gene on etanercept treatment in rheumatoid arthritis.
Guis S; Balandraud N; Bouvenot J; Auger I; Toussirot E; Wendling D; Mattei JP; Nogueira L; Mugnier B; Legeron P; Landt O; Serre G; Roudier J; Roudier C
Arthritis Rheum; 2007 Dec; 57(8):1426-30. PubMed ID: 18050183
[TBL] [Abstract][Full Text] [Related]
3. The -308 tumour necrosis factor-alpha gene polymorphism predicts therapeutic response to TNFalpha-blockers in rheumatoid arthritis and spondyloarthritis patients.
Seitz M; Wirthmüller U; Möller B; Villiger PM
Rheumatology (Oxford); 2007 Jan; 46(1):93-6. PubMed ID: 16720636
[TBL] [Abstract][Full Text] [Related]
4. Association between the level of circulating bioactive tumor necrosis factor alpha and the tumor necrosis factor alpha gene polymorphism at -308 in patients with rheumatoid arthritis treated with a tumor necrosis factor alpha inhibitor.
Marotte H; Arnaud B; Diasparra J; Zrioual S; Miossec P
Arthritis Rheum; 2008 May; 58(5):1258-63. PubMed ID: 18438841
[TBL] [Abstract][Full Text] [Related]
5. Tumour necrosis factor-alpha (TNF-alpha) levels and influence of -308 TNF-alpha promoter polymorphism on the responsiveness to infliximab in patients with rheumatoid arthritis.
Cuchacovich M; Ferreira L; Aliste M; Soto L; Cuenca J; Cruzat A; Gatica H; Schiattino I; Pérez C; Aguirre A; Salazar-Onfray F; Aguillón JC
Scand J Rheumatol; 2004; 33(4):228-32. PubMed ID: 15370717
[TBL] [Abstract][Full Text] [Related]
6. Influence of variants of Fc gamma receptors IIA and IIIA on the American College of Rheumatology and European League Against Rheumatism responses to anti-tumour necrosis factor alpha therapy in rheumatoid arthritis.
Cañete JD; Suárez B; Hernández MV; Sanmartí R; Rego I; Celis R; Moll C; Pinto JA; Blanco FJ; Lozano F
Ann Rheum Dis; 2009 Oct; 68(10):1547-52. PubMed ID: 18930989
[TBL] [Abstract][Full Text] [Related]
7. Fcgamma receptor type IIIA genotype and response to tumor necrosis factor alpha-blocking agents in patients with rheumatoid arthritis.
Kastbom A; Bratt J; Ernestam S; Lampa J; Padyukov L; Söderkvist P; Skogh T
Arthritis Rheum; 2007 Feb; 56(2):448-52. PubMed ID: 17265480
[TBL] [Abstract][Full Text] [Related]
8. Messenger ribonucleic acid expression profile in peripheral blood cells from RA patients following treatment with an anti-TNF-alpha monoclonal antibody, infliximab.
Sekiguchi N; Kawauchi S; Furuya T; Inaba N; Matsuda K; Ando S; Ogasawara M; Aburatani H; Kameda H; Amano K; Abe T; Ito S; Takeuchi T
Rheumatology (Oxford); 2008 Jun; 47(6):780-8. PubMed ID: 18388148
[TBL] [Abstract][Full Text] [Related]
9. Responsiveness to anti-tumour necrosis factor alpha therapy is related to pre-treatment tissue inflammation levels in rheumatoid arthritis patients.
van der Pouw Kraan TC; Wijbrandts CA; van Baarsen LG; Rustenburg F; Baggen JM; Verweij CL; Tak PP
Ann Rheum Dis; 2008 Apr; 67(4):563-6. PubMed ID: 18042642
[TBL] [Abstract][Full Text] [Related]
10. Titration of infliximab treatment in rheumatoid arthritis patients based on response patterns.
Flendrie M; Creemers MC; van Riel PL
Rheumatology (Oxford); 2007 Jan; 46(1):146-9. PubMed ID: 16782732
[TBL] [Abstract][Full Text] [Related]
11. Associations between tumor necrosis factor-alpha (TNF-alpha) -308 and -238 G/A polymorphisms and shared epitope status and responsiveness to TNF-alpha blockers in rheumatoid arthritis: a metaanalysis update.
Lee YH; Ji JD; Bae SC; Song GG
J Rheumatol; 2010 Apr; 37(4):740-6. PubMed ID: 20194454
[TBL] [Abstract][Full Text] [Related]
12. The influence of a polymorphism at position -857 of the tumour necrosis factor alpha gene on clinical response to etanercept therapy in rheumatoid arthritis.
Kang CP; Lee KW; Yoo DH; Kang C; Bae SC
Rheumatology (Oxford); 2005 Apr; 44(4):547-52. PubMed ID: 15695296
[TBL] [Abstract][Full Text] [Related]
13. Tumor necrosis factor alpha haplotypes versus tumor necrosis factor alpha -308 G/A polymorphism in the prediction of infliximab treatment efficacy in rheumatoid arthritis.
Mugnier B; Roudier J
Arthritis Rheum; 2004 Dec; 50(12):4075-6; author reply 4076-7. PubMed ID: 15593229
[No Abstract] [Full Text] [Related]
14. Interleukin 10 and tumor necrosis factor-alpha genotypes in rheumatoid arthritis--association with clinical response to glucocorticoids.
de Paz B; Alperi-López M; Ballina-García FJ; Prado C; Mozo L; Gutiérrez C; Suárez A
J Rheumatol; 2010 Mar; 37(3):503-11. PubMed ID: 20080912
[TBL] [Abstract][Full Text] [Related]
15. Treatment with tumour necrosis factor alpha antagonists in patients with rheumatoid arthritis induces anticardiolipin antibodies.
Jonsdottir T; Forslid J; van Vollenhoven A; Harju A; Brannemark S; Klareskog L; van Vollenhoven RF
Ann Rheum Dis; 2004 Sep; 63(9):1075-8. PubMed ID: 15066863
[TBL] [Abstract][Full Text] [Related]
16. Effects of infliximab therapy on gene expression levels of tumor necrosis factor alpha, tristetraprolin, T cell intracellular antigen 1, and Hu antigen R in patients with rheumatoid arthritis.
Sugihara M; Tsutsumi A; Suzuki E; Wakamatsu E; Suzuki T; Ogishima H; Hayashi T; Chino Y; Ishii W; Mamura M; Goto D; Matsumoto I; Ito S; Sumida T
Arthritis Rheum; 2007 Jul; 56(7):2160-9. PubMed ID: 17599736
[TBL] [Abstract][Full Text] [Related]
17. Individualized monitoring of drug bioavailability and immunogenicity in rheumatoid arthritis patients treated with the tumor necrosis factor alpha inhibitor infliximab.
Bendtzen K; Geborek P; Svenson M; Larsson L; Kapetanovic MC; Saxne T
Arthritis Rheum; 2006 Dec; 54(12):3782-9. PubMed ID: 17133559
[TBL] [Abstract][Full Text] [Related]
18. Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register.
Hyrich KL; Watson KD; Silman AJ; Symmons DP;
Rheumatology (Oxford); 2006 Dec; 45(12):1558-65. PubMed ID: 16705046
[TBL] [Abstract][Full Text] [Related]
19. Potential novel biomarkers of disease activity in rheumatoid arthritis patients: CXCL13, CCL23, transforming growth factor alpha, tumor necrosis factor receptor superfamily member 9, and macrophage colony-stimulating factor.
Rioja I; Hughes FJ; Sharp CH; Warnock LC; Montgomery DS; Akil M; Wilson AG; Binks MH; Dickson MC
Arthritis Rheum; 2008 Aug; 58(8):2257-67. PubMed ID: 18668547
[TBL] [Abstract][Full Text] [Related]
20. C-reactive protein as a predictor of infliximab treatment outcome in patients with rheumatoid arthritis: defining subtypes of nonresponse and subsequent response to etanercept.
Buch MH; Seto Y; Bingham SJ; Bejarano V; Bryer D; White J; Emery P
Arthritis Rheum; 2005 Jan; 52(1):42-8. PubMed ID: 15641046
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
